Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

An Open-Label, Multicenter, Single-Arm Phase 1 Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61 in Subjects With Advanced Solid Tumors

This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.

Study Overview

• Status: Recruiting
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Drug: ASC61 200 mg 1; Drug: ASC61 200 mg 2; Drug: ASC61 300 mg; Drug: ASC61 400 mg; Drug: ASC61 600 mg

Detailed Description

Except for the first starting dose of 200 mg once daily (QD), a traditional "3 + 3 design" will be followed for dose finding with dose escalation and/or de escalation as appropriate. Each subject in each dose cohort will use 2 dose schedules: single dose on Day 1 (D1), and repeated doses on daily basis for 28 days starting from Day 3. One treatment cycle is 28 days. Subjects will be sequentially enrolled in a dose-escalation design to receive ASC61 at initial dose of 200 mg QD. Subsequent doses of 200 mg twice a day (BID), 300 mg BID, 400 mg BID, and 600 mg BID are planned.

• Study Type: Interventional
• Enrollment (Estimated): 16
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Ascletis Study Doctor; Phone Number: +86 571 85389730; Email: clinicaltrials@ascletis.com
• Study Contact Backup: Name: Handan He; Phone Number: +86 571 85389730; Email: handan.he@ascletis.com

Study Locations

• United States
  • California
    • Encinitas, California, United States, 92024
      • Recruiting
      • California Cancer Associates for Research & Excellence (cCARE)
      • Principal Investigator: Alberto Bessudo, MD
      • Contact: Mona Bilawa, Research Administrator; Phone Number: 507 760-747-8935; Email: MBilawa@ccare.com
    • Fresno, California, United States, 93720
      • Recruiting
      • California Cancer Associates for Research & Excellence (cCARE)
      • Contact: Christina Spencer, Research Administrator; Phone Number: 760-452-3909; Email: cspencer@ccare.com
      • Principal Investigator: Steven Hager, DO
    • San Marcos, California, United States, 92069
      • Recruiting
      • California Cancer Associates for Research & Excellence (cCARE)
      • Principal Investigator: Alberto Bessudo, MD
      • Contact: Mona Bilawa, Research Administrator; Phone Number: 507 760-747-8935; Email: MBilawa@ccare.com
  • Nebraska
    • Omaha, Nebraska, United States, 68130
      • Recruiting
      • Nebraska Cancer Specialists
      • Contact: Erin Smith; Phone Number: 531-329-3667; Email: esmith@nebraskacancer.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults ≥ 18 years of age at the time of screening
• Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available, regardless of cancer stage and previous experienced therapies
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• At least one measurable lesion, as defined by RECIST 1.1

Exclusion Criteria:

• Known symptomatic brain metastases requiring steroids
• Known history of another primary solid tumor
• Subjects discontinued prior therapy with immune checkpoints due to toxicity if previously received therapy with this class of drugs
• Known history of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or evidence of active pneumonia or pneumonitis
• Gastrointestinal disorders that might affect drug absorption

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ASC61 200 mg 1; ASC61 200 mg orally once	Drug: ASC61 200 mg 1; 200mg of ASC61 orally once daily for cycles of 28 days
Experimental: ASC61 200 mg 2; ASC61 200 mg orally twice daily	Drug: ASC61 200 mg 2; 200 mg of ASC61 orally twice daily for cycles of 28 days
Experimental: ASC61 300 mg; ASC61 300 mg orally twice daily	Drug: ASC61 300 mg; 300 mg of ASC61 orally twice daily for cycles of 28 days
Experimental: ASC61 400 mg; ASC61 400 mg orally twice daily	Drug: ASC61 400 mg; 400 mg of ASC61 orally twice daily for cycles of 28 days
Experimental: ASC61 600 mg; ASC61 600 mg orally twice daily	Drug: ASC61 600 mg; 600 mg of ASC61 orally twice daily for cycles of 28 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients who experience DLTs	The primary endpoint of this study is the proportion of the patients who experience DLTs. The MTD (Maximum Tolerated Dose) will be determined based on the dose escalation cohorts. The evaluation period for DLTs will be 28 days following treatment of PD1-PDL1 inhibitor	From baseline to 28 days of treatment
Dose(s) of ASC 61 to be examined in Part 2 and the recommended Phase 2 dose(s)	Maximum serum concentration (Cmax) of ASC61, Area under the serum concentrations of ASC61 versus time curve (AUC) and Half-life (t1/2) of serum concentrations of ASC61)	From first dose of ASC61 (Day 1) until 90 days after the last dose

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of ASC61 subjects with a best response of Complete Response or Partial Response (Objective Response Rate)	Baseline until confirmed disease progression (CR or PR) (up to 1 year)
Percentage of ASC61 subjects with Complete Response, Partial Response, or Stable Disease (Disease Control Rate)	Baseline until confirmed disease progression (CR or PR) (up to 1 year)
Length of time that ASC61 subjects continue to respond to treatment without disease progression (Duration of response)	From the date of first confirmed CR or PR until the first date of recurrent or progressive disease (up to 1 year)
Length of time between first dosing and disease progression (Progression-Free survival)	From first dose of ASC61 (Day 1) until death (up to 1 year)

Collaborators and Investigators

• Sponsor: Gannex Pharma Co., Ltd.
• Collaborators: Ascletis Pharmaceuticals Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): August 2, 2022
• Primary Completion (Estimated): December 20, 2024
• Study Completion (Estimated): December 20, 2024

Study Registration Dates

• First Submitted: February 23, 2022
• First Submitted That Met QC Criteria: March 10, 2022
• First Posted (Actual): March 18, 2022

Study Record Updates

• Last Update Posted (Actual): April 3, 2024
• Last Update Submitted That Met QC Criteria: April 2, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: ASC61-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No